Blood cytokine patterns suggest a modest inflammation phenotype in subjects with long-chain fatty acid oxidation disorders.
Adolescent
Adult
Biomarkers
/ blood
Carnitine O-Palmitoyltransferase
/ deficiency
Case-Control Studies
Child
Cytokines
/ blood
Exercise
Fatty Acids
/ metabolism
Female
Humans
Inflammation Mediators
/ blood
Interferon-gamma
/ blood
Interleukin-10
/ blood
Interleukin-8
/ blood
Lipid Metabolism, Inborn Errors
/ blood
Long-Chain-3-Hydroxyacyl-CoA Dehydrogenase
/ deficiency
Male
Oxidation-Reduction
Phenotype
Postprandial Period
Time Factors
Young Adult
Carnitine
caspase-3
immunometabolism
Journal
Physiological reports
ISSN: 2051-817X
Titre abrégé: Physiol Rep
Pays: United States
ID NLM: 101607800
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
01
02
2019
revised:
04
03
2019
accepted:
05
03
2019
entrez:
27
3
2019
pubmed:
27
3
2019
medline:
28
4
2020
Statut:
ppublish
Résumé
Excessive cellular accumulation or exposure to lipids such as long-chain acylcarnitines (LCACs), ceramides, and others is implicated in cell stress and inflammation. Such a situation might manifest when there is a significant mismatch between long-chain fatty acid (LCFA) availability versus storage and oxidative utilization; for example, in cardiac ischemia, increased LCACs may contribute to tissue cell stress and infarct damage. Perturbed LCFAβ-oxidation is also seen in fatty acid oxidation disorders (FAODs). FAODs typically manifest with fasting- or stress-induced symptoms, and patients can manage many symptoms through control of diet and physical activity. However, episodic clinical events involving cardiac and skeletal muscle myopathies are common and can present without an obvious molecular trigger. We have speculated that systemic or tissue-specific lipotoxicity and activation of inflammation pathways contribute to long-chain FAOD pathophysiology. With this in mind, we characterized inflammatory phenotype (14 blood plasma cytokines) in resting, overnight-fasted (~10 h), or exercise-challenged subjects with clinically well-controlled long-chain FAODs (n = 12; 10 long-chain 3-hydroxyacyl-CoA dehydrogenase [LCHAD]; 2 carnitine palmitoyltransferase 2 [CPT2]) compared to healthy controls (n = 12). Across experimental conditions, concentrations of three cytokines were modestly but significantly increased in FAOD (IFNγ, IL-8, and MDC), and plasma levels of IL-10 (considered an inflammation-dampening cytokine) were significantly decreased. These novel results indicate that while asymptomatic FAOD patients do not display gross body-wide inflammation even after moderate exercise, β-oxidation deficiencies might be associated with chronic and subtle activation of "sterile inflammation." Further studies are warranted to determine if inflammation is more apparent in poorly controlled long-chain FAOD or when long-chain FAOD-associated symptoms are present.
Identifiants
pubmed: 30912279
doi: 10.14814/phy2.14037
pmc: PMC6434073
doi:
Substances chimiques
Biomarkers
0
CXCL8 protein, human
0
Cytokines
0
Fatty Acids
0
IFNG protein, human
0
IL10 protein, human
0
Inflammation Mediators
0
Interleukin-8
0
Interleukin-10
130068-27-8
Interferon-gamma
82115-62-6
Long-Chain-3-Hydroxyacyl-CoA Dehydrogenase
EC 1.1.1.211
Carnitine O-Palmitoyltransferase
EC 2.3.1.21
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14037Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR000002
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002369
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01DK078328
Pays : United States
Organisme : NIDDK NIH HHS
ID : K01DK071869
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR000133
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01DK078328-02S1
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK078775
Pays : United States
Informations de copyright
© 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society.
Références
Diabetes. 1986 Aug;35(8):906-10
pubmed: 3732631
Sci Rep. 2016 Nov 28;6:37941
pubmed: 27892502
Nat Rev Endocrinol. 2015 Oct;11(10):617-25
pubmed: 26303601
Clin Exp Pharmacol Physiol. 1997 Nov;24(11):889-95
pubmed: 9363377
FASEB J. 2015 Jan;29(1):336-45
pubmed: 25342132
Genet Med. 2011 Mar;13(3):230-54
pubmed: 21325949
Am J Physiol Endocrinol Metab. 2013 Nov 15;305(10):E1299-308
pubmed: 24064340
Am J Physiol. 1993 Sep;265(3 Pt 1):E380-91
pubmed: 8214047
Mol Genet Metab. 2012 Jan;105(1):110-5
pubmed: 22030098
Obesity (Silver Spring). 2010 Sep;18(9):1695-700
pubmed: 20111019
Am J Physiol Endocrinol Metab. 2014 Jun 15;306(12):E1378-87
pubmed: 24760988
J Nutr. 2009 Jun;139(6):1073-81
pubmed: 19369366
Diabetes Res Clin Pract. 1995 Oct;30(1):1-7
pubmed: 8745200
J Inherit Metab Dis. 2016 May;39(3):399-408
pubmed: 26907176
Anal Bioanal Chem. 2003 Jan;375(2):200-10
pubmed: 12560963
Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1292-1299
pubmed: 28392417
Am J Physiol Endocrinol Metab. 2015 Jun 1;308(11):E990-E1000
pubmed: 25852008
Biosci Rep. 2015 Nov 20;36(1):e00281
pubmed: 26589966
Diabetologia. 2015 Aug;58(8):1845-54
pubmed: 26067360
Mol Genet Metab. 2008 Aug;94(4):422-7
pubmed: 18550408
Adv Nutr. 2017 Mar 15;8(2):213-225
pubmed: 28298267
Cell Metab. 2008 Jan;7(1):45-56
pubmed: 18177724
Dev Cell. 2017 Jul 10;42(1):9-21.e5
pubmed: 28697336
Mediators Inflamm. 2017;2017:4806541
pubmed: 29269995
PLoS One. 2010 Jul 12;5(7):e11519
pubmed: 20634953
PLoS One. 2012;7(6):e38812
pubmed: 22701716
Biochem J. 2016 May 1;473(9):1191-202
pubmed: 26936967
Obesity (Silver Spring). 2011 Apr;19(4):792-9
pubmed: 20595951
Exp Physiol. 2017 Jan 1;102(1):48-69
pubmed: 27730694
J Biol Chem. 1978 Jun 25;253(12):4310-8
pubmed: 207696
Biochemistry. 1996 Jun 18;35(24):7903-9
pubmed: 8672492
Prostate. 2016 Oct;76(14):1326-37
pubmed: 27403764
Pharmacol Res. 2016 Nov;113(Pt B):771-780
pubmed: 26850121
Physiol Rep. 2019 Mar;7(6):e14037
pubmed: 30912279
Pharmacol Res. 2014 Jul;85:33-8
pubmed: 24836867
Metabolism. 1981 Apr;30(4):393-401
pubmed: 6111018